Ofatumumab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to determine the efficacy of ofatumumab in patients with
relapsed nodular lymphocyte predominant Hodgkin lymphoma (NLPHL).